Gilead and kite showcase continued progress in transforming blood cancer care with new cell therapy data at ash 2025

Foster city, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) and kite, a gilead company, will present 21 abstracts, including 5 oral presentations, during the 67th american society of hematology (ash) annual meeting and exposition (december 6-9). these data showcase kite's continued progress in transforming blood cancer care and expanding the reach and impact of car t-cell therapy. “kite is dedicated to advancing cell therapy as a path to cures, and our data at ash will reflect me.
ASH Ratings Summary
ASH Quant Ranking